Table 2.

Adjusted models of 4-year all-cause and cardiovascular mortality

	All-Cause Mortality		Cardiovascular Mortality
	Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
PHQ-2 (+) vs. PHQ-2 (−)	1.50 (1.02–2.20)	.04	1.44 (0.91–2.29)	.12
Female vs. male gender	1.18 (0.88–1.58)	.28	1.22 (0.85–1.75)	.28
Age (≥65 vs. <65 years old)	2.40 (1.73–3.34)	<.01	2.36 (1.57–3.54)	<.01
LVEF (≤30% vs. >30%)	1.19 (0.86–1.65)	.30	1.34 (0.89–2.04)	.16
NYHA class (III–IV vs. II)	1.35 (0.98–1.86)	.06	1.17 (0.80–1.72)	.42
Anxiety disorder	0.84 (0.58–1.21)	.34	0.95 (0.61–1.49)	.83
COPD	1.42 (1.05–1.93)	.02	1.34 (0.92–1.96)	.12
Renal insufficiency	2.07 (1.52–2.81)	<.01	1.90 (1.30–2.78)	<.01
ACE-I or ARB	0.90 (0.65–1.23)	.49	0.74 (0.51–1.08)	.12
Beta-blocker	0.76 (0.53–1.09)	.13	0.83 (0.53–1.29)	.40
Coumadin	1.10 (0.82–1.47)	.52	1.17 (0.82–1.68)	.38
Diabetes	1.50 (1.13–2.00)	<.01	1.75 (1.23–2.48)	<.01
Hemoglobin (<10 vs. ≥ 10 g/dl)	1.55 (1.02–2.36)	.04	1.35 (0.79–2.31)	.27
Sodium (<136 vs. ≥136 mmol/L)	1.01 (0.69–1.46)	.98	0.96 (0.60–1.53)	.86
Diastolic BP (per 10-unit increase)	1.03 (0.97–1.10)	.38	1.05 (0.98–1.14)	.18
Systolic BP (per 10-unit increase)	0.97 (0.91–1.04)	.38	0.95 (0.88–1.03)	.21

Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CABG, coronary artery bypass graft; CI, confidence interval; COPD, chronic obstructive lung disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PHQ, Patient Health Questionnaire; SF-12 MCS, Medical Outcomes Study Short Form Mental Component Scale; SF-12 PCS, Medical Outcomes Study Short Form Physical Component Scale.